RemeGen Co., Ltd. (SHA:688331)

China flag China · Delayed Price · Currency is CNY
90.18
+2.98 (3.42%)
Oct 24, 2025, 3:00 PM CST
3.42%
Market Cap47.58B
Revenue (ttm)2.07B
Net Income (ttm)-1.14B
Shares Outn/a
EPS (ttm)-2.11
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,811,800
Average Volume8,032,318
Open87.56
Previous Close87.20
Day's Range87.01 - 90.83
52-Week Range24.11 - 118.88
Beta0.88
RSI43.88
Earnings DateOct 30, 2025

About RemeGen

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of various cancers. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial gro... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 2,999
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688331
Full Company Profile

Financial Performance

In 2024, RemeGen's revenue was 1.72 billion, an increase of 58.54% compared to the previous year's 1.08 billion. Losses were -1.47 billion, -2.84% less than in 2023.

Financial Statements

News

There is no news available yet.